The sermorelin peptide explained by an insider: how it works, what the human trials found, what clinic sites skip, and what to check before you inject.
Sermorelin Peptide: Here’s Why the 11-Minute Detail Changes Everything
The half-life of the sermorelin peptide is about eleven minutes. Peak levels hit 5 to 20 minutes after a subcutaneous injection, and the half-life is 11 to 12 minutes [1]. Inject it at bedtime and most of it is gone before you've finished scrolling.
Every promise on a sermorelin clinic's homepage (deeper sleep, leaner body, "recharged" energy) depends on what a signal that brief can do over months. Clinics rarely bring it up, because the honest answer is more interesting than the pitch and less profitable. Here's the answer, plus what you should know before injecting a peptide that has been off the market as a branded drug since 2008.
What the sermorelin peptide actually is
Sermorelin is the first 29 amino acids of growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to tell the pituitary to release growth hormone. Those 29 amino acids are the active part, which is why it's also written GHRH(1-29). It is not growth hormone. It's a messenger asking your pituitary to make some.
That distinction is the whole pitch. GH comes in roughly ten pulses a day, with the biggest one shortly after deep sleep begins, and output falls from about 150 µg/kg/day at puberty to about 25 by age 55 [7]. Injected GH bypasses the pituitary. A GHRH analog goes through it, so your own feedback brakes stay in the loop, which is the argument proponents make for it [8]. That's a mechanistic argument, and a decent one, but it isn't a demonstrated outcome. The rest of this article is about the gap between the two.
The history clinics gloss over
Sermorelin was approved in 1997 to treat growth hormone deficiency in children, then discontinued in 2008 for commercial reasons [9]. Geref was a once-daily bedtime injection sold in 0.5 mg and 1.0 mg strengths [2].
Healthy adults chasing a physique edge were never the approved population. Today sermorelin is a compounded product, and compounded drugs aren't FDA-approved, so the agency doesn't review their safety, effectiveness or quality before they're marketed [11]. The "FDA-approved" line on clinic sites refers to a different product used in different people. As Dr. Jen Gunter put it in a November 2026 critique, an approval covers the labeled indication and dosing, not a compounded vial sold for wellness [10].
The eleven-minute problem
The label data describes a short pulse: about 6% absolute bioavailability after a subcutaneous dose, and rapid clearance from the circulation [1]. For a hormone system that runs on pulses, that might be fine. The trials suggest it depends on how often you pulse.
- Corpas, 1992: Ten older men took 0.5 mg or 1 mg twice daily for 14 days. Both doses raised 24-hour GH and IGF-1 in a dose-related way [4].
- Vittone, 1997: Eleven healthy men aged 64 to 76 with low IGF-1 injected 2 mg nightly for 6 weeks. Nocturnal GH release rose, but IGF-1 and DEXA body-composition measures didn't change, and the authors concluded single nightly doses are less effective than multiple daily doses [5].
- Khorram, 1997: Nineteen adults aged 55 to 71 injected a close sermorelin analog nightly for 16 weeks after 4 weeks of placebo. GH rose, lean mass rose in men only, skin thickness rose in both sexes, and the only adverse effect was a transient lipid elevation [6]. That was a modified analog rather than sermorelin itself, and it had no parallel placebo group [10].
My read, and it's an interpretation from small studies rather than a settled finding: a single nightly dose gives you a GH bump, but in the one trial that measured IGF-1 on that schedule, IGF-1 didn't move. IGF-1 is what clinics test and what carries many of GH's downstream effects. Dosing frequency may matter more than almost anything else, and almost nobody mentions it.
Doses are the other quiet detail. The trials above used 0.5 to 2 mg per injection. Gunter notes that one major telehealth provider starts at 0.2 mg, and she couldn't find any dose-finding study behind that number [10]. Don't treat trial doses as a recommendation, but do treat the mismatch as a question.
What the human evidence adds up to
The research is small, short and built on intermediate endpoints. A review of GHRH and secretagogue research notes that every study to date has focused on manageable intermediate endpoints rather than long-term clinical outcomes [12]. The largest sermorelin trial Gunter found was a randomized placebo-controlled study of 89 adults aged 60 to 85, using 1 mg nightly for about five to six months, which showed some cognitive improvement of unclear clinical meaning [10][17]. Researcher Alexander Pastuszak notes there are no large randomized trials in healthy adults testing sermorelin for performance, body composition or longevity [9].
Consider the ceiling, too. In older adults, actual growth hormone added about 4.6 pounds of lean mass with a similar fat loss, but came with swelling, joint pain, carpal tunnel and some cases of diabetes, and it didn't improve mobility [9]. Lean mass includes water. A GHRH analog with a feedback-capped GH response has little reason to beat that ceiling. If the full-dose hormone can't make older people walk better, the gentler version has a hard sell.
Claim: What the evidence supports
- Raises GH: Yes, consistently. Nocturnal GH rose even on a single nightly dose [5].
- Raises IGF-1: Schedule-dependent. Seen with twice-daily dosing [4], not with one nightly dose in a separate trial [5].
- Builds muscle, cuts fat: Lean mass rose in men only in one 16-week analog study [6]. No sermorelin trial showing performance gains in healthy adults was found.
- Better sleep, recovery, "energy": Heavily marketed. The controlled studies reviewed here weren't designed to test these.
- Anti-aging: Unproven. The Endocrine Society's 2023 statement says no GH-boosting therapy is approved for anti-aging, and rhGH and secretagogue studies haven't shown benefits that outweigh risks [10][16].
- Works the same in women: Almost no data. Gunter found one peer-reviewed study in adult women [10].
Side effects, and what "natural" glosses over
The label-documented effects are mild. Injection-site reactions occurred in about 1 in 6 patients in the pediatric trials. Other effects, each under 1%, included headache, flushing, dysphagia, dizziness, hyperactivity, somnolence and hives, and hypothyroidism occurred in 6.5% of patients during therapy [1]. That was a pediatric population, so extrapolate carefully. Concomitant glucocorticoid therapy may blunt the response [3].
The real unknown is chronic elevation of GH and IGF-1 in healthy adults. Pastuszak describes seeing joint pain in his practice, a sign of excess growth hormone, and endocrinologist Brad Anawalt links excess GH to heart disease, stroke and colon-cancer risk [9]. That describes the extreme end, acromegaly, not a typical sermorelin user. Still, the label for tesamorelin, a related GHRH analog, warns about glucose intolerance and diabetes, fluid retention, joint pain and carpal tunnel [10]. The feedback-loop argument is real pharmacology. What's missing is the long-term trial showing where the cap sits.
The vial problem
Geref's pediatric safety record doesn't transfer to whatever is in a compounded vial. Gunter points out that the source, purity and potency of a compounded product can't be assumed to match the approved one [10]. The quality picture outside licensed pharmacies is worse: a not-yet-peer-reviewed analysis found that roughly 40 to 70 percent of thousands of gray-market peptide samples, sermorelin included, failed basic quality criteria, and about 15 percent of one subset showed endotoxin [9]. "Research use only" sellers are the group that analysis points at.
On regulation, here's the short version. HHS's October 2026 draft interim policy covers six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 [11]. Sermorelin isn't on that list, so the peptide headlines of 2026 aren't about it. Clinic sites can't agree on its exact compounding category either: one calls it Category 1 [14], another says it's under review [15], and a third says it isn't on FDA's category lists at all [13]. Treat that disagreement as a data point about clinic-site reliability, and ask the pharmacy directly.
Sermorelin vs. the rest of the alphabet
Tesamorelin is the grown-up cousin. It was approved in 2010 for HIV-associated lipodystrophy, and visceral fat fell about 15% in a trial of over 400 people [9]. That was a specific disease population, and the goal was fat reduction, not muscle. CJC-1295, ipamorelin, GHRP-2 and GHRP-6 have never been FDA-approved. They raise GH, but there's no solid proof they change muscle or fat [9]. Stacking several peptides also makes it impossible to tell what any single one is doing [9].
The bottom line
The sermorelin peptide reliably does one thing: it raises growth hormone. Whether that turns into anything you can see, lift or feel is unproven in healthy adults. Whether the vial matches the one in the trials is a separate question. The levers with real data (training, protein, sleep, creatine) beat it on every outcome that's been measured.
If you go the prescription route anyway, demand three things. Use a licensed pharmacy, not a research-use-only seller. Get baseline and follow-up labs, at least IGF-1, glucose and lipids. And find a prescriber who can explain the dosing-frequency question above without changing the subject.
Eleven minutes is a short time to carry that much marketing.
References
- GlobalRx. Sermorelin acetate (Geref) prescribing information, clinical pharmacology and adverse reactions. https://globalrph.com/rx-list/sermorelin-acetate-drug
- American Academy of Family Physicians. Clinical Briefs: Geref (sermorelin acetate for injection). American Family Physician, 1998. https://www.aafp.org/afp/1998/1015/p1484
- RxList. Sermorelin acetate: side effects, dosage and interactions. https://www.rxlist.com/sermorelin-acetate-side-effects-drug-center.htm
- Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone-releasing hormone-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://academic.oup.com/jcem/article/75/2/530/2649366
- Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. https://pubmed.ncbi.nlm.nih.gov/9005976/
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. https://pubmed.ncbi.nlm.nih.gov/9141536/
- Hersch EC, Merriam GR. Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus? Clin Interv Aging. 2008;3(1):121-129. https://pmc.ncbi.nlm.nih.gov/articles/PMC2544358
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308 (editorial). https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646
- Youmshajekian L. The murky science behind human growth hormone peptides. Scientific American. https://www.scientificamerican.com/article/growth-hormone-peptides-promise-to-stall-aging-but-does-the-science-stack-up/
- Gunter J. Sermorelin: The peptide promise outruns the evidence. The Vajenda, November 2, 2026 (expert commentary). https://vajenda.substack.com/p/sermorelin-the-peptide-promise-outruns
- U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (draft policy and appendices), 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- Review of GHRH and GH secretagogue research in aging. Endocrine, DOI 10.1385/ENDO:22:1:41. https://link.springer.com/article/10.1385/ENDO:22:1:41
- PortraitCare. Is sermorelin FDA approved? GEREF history and 2026 status (clinic-affiliated source, used only to show disagreement on compounding status). https://www.portraitcare.com/post/is-sermorelin-fda-approved
- MyPeptideMatch. Is sermorelin FDA approved? Legal status and regulations (commercial source, used only to show disagreement on compounding status). https://www.mypeptidematch.com/blog/sermorelin-legal-status
- Clinical Peptide. Is sermorelin FDA approved? Regulatory history and current status (commercial source, used only to show disagreement on compounding status). https://clinicalpeptide.org/blog/sermorelin-fda-approved-regulatory-history/
- Cappola AR, Auchus RJ, El-Hajj Fuleihan G, et al. Hormones and Aging: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab. 2023;108(8):1835-1874. Cited via [10].
- Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006;27(2):318-323. Cited via [10].
FAQ
Q: What is the sermorelin peptide?
A: Sermorelin is a synthetic peptide made of the first 29 amino acids of growth hormone-releasing hormone (GHRH 1-29). It signals the pituitary gland to release growth hormone and is not growth hormone itself [7][8].
Q: Is sermorelin FDA-approved?
A: Sermorelin was FDA-approved in 1997 as Geref for children with growth hormone deficiency, and the manufacturer discontinued it in 2008 for commercial reasons [9]. Compounded sermorelin sold today is not FDA-approved, and the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed [11].
Q: How long does sermorelin last in the body?
A: Sermorelin's half-life is about 11 to 12 minutes after intravenous or subcutaneous administration, with peak blood levels 5 to 20 minutes after a subcutaneous injection [1].
Q: Does sermorelin raise IGF-1?
A: It depends on the dosing schedule. In one trial, older men injecting twice daily showed dose-related increases in GH and IGF-1 [4], while another trial using a single nightly dose raised nocturnal GH without changing IGF-1 [5]. Both studies were small and short.
Does sermorelin build muscle or burn fat?
There is no large randomized trial showing that sermorelin improves muscle, fat loss or performance in healthy adults [9]. A 16-week study of a close sermorelin analog found lean mass increased in men but not in women, and it had no parallel placebo group [6][10].
What are the side effects of sermorelin?
In pediatric trials, about 1 in 6 patients had injection-site reactions, and several other effects were rare:
- Injection-site pain, swelling or redness: about 1 in 6 patients
- Headache, flushing, dizziness and hives: each occurred in under 1% [1]
Long-term effects of raising growth hormone and IGF-1 in healthy adults have not been established [10].
Is compounded sermorelin the same as Geref?
No. Geref's safety record comes from its approved pediatric use, and the source, purity and potency of a compounded product cannot be assumed to match it [10]. Quality problems are most documented with gray-market peptides sold outside licensed pharmacies [9].
How does sermorelin compare to tesamorelin, CJC-1295 and ipamorelin?
- Tesamorelin is FDA-approved for HIV-associated lipodystrophy and reduced visceral fat by about 15% in a trial of over 400 people.
- CJC-1295, ipamorelin, GHRP-2 and GHRP-6 have never been FDA-approved and raise GH without solid proof that they change muscle or fat [9].
Does sermorelin work for women?
Evidence in women is very limited. One commentator found a single peer-reviewed sermorelin study in adult women, and a related analog study showed lean-mass and well-being benefits in men but not in women [6][10].